Lipid lowering goals: back to nature?

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Preventive Cardiology

Background:

• Hypercholesterolemia is a primary risk factor for atherosclerosis.
• Current guidelines suggest target low-density lipoprotein cholesterol (LDL-C) levels, but evolutionary and comparative data suggest much lower levels may be optimal.
• Untreated Western populations average ~130 mg/dl LDL-C, while wild animals and primitive human societies exhibit much lower levels.

Purpose of the Study:

• To explore the concept of 'how low should LDL-C go?' for cardiovascular disease prevention.
• To evaluate the potential of achieving significantly lower LDL-C targets than currently recommended.
• To assess the safety and potential efficacy of novel lipid-lowering therapies for extreme LDL-C reduction.

Main Methods:

• Extrapolation of data from meta-analyses of large clinical trials.
• Comparative analysis of lipid levels in wild animals and primitive human societies.
• Review of current and emerging lipid-lowering therapies.

Main Results:

• Extrapolated data suggest cardiovascular event rates approach zero at LDL-C <60 mg/dl (primary prevention) and ~30 mg/dl (secondary prevention).
• These target levels are substantially lower than current guideline recommendations.
• Emerging potent lipid-lowering therapies may enable achievement of these very low LDL-C goals.

Conclusions:

• Achieving very low LDL-C levels (<60 mg/dl or lower) may offer significant cardiovascular benefits.
• Current evidence suggests these low lipid levels are safe, but long-term generalizability requires further study.
• The clinical benefit of extreme LDL-C reduction on cardiovascular complications needs definitive proof in diverse populations.